Oxis International, Inc. (OTCQB: OXIS and EURONEXT PARIS OXI.PA), through its wholly owned subsidiary Oxis Biotech, Inc., is engaged in the development of immunotherapies for the treatment of cancer. Oxis' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis. Oxis' lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.

Multiple myeloma is a type of cancer that forms in white blood cells, and affects about 26,850 people annually in the USA causing about 11,240 deaths per year. Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells. Multiple myeloma is also characterized by destructive lytic bone lesions (rounded, punched-out areas of bone), diffuse osteoporosis, bone pain, and the production of abnormal proteins which accumulate in the urine. Anemia is also present in most multiple myeloma patients at the time of diagnosis and during follow-up. Anemia in multiple myeloma is multifactorial, and is secondary to bone marrow replacement by malignant plasma cells, chronic inflammation, relative erythropoietin deficiency, and vitamin deficiency. Plasma cell leukemia, a condition in which plasma cells comprise greater than 20% of peripheral leukocytes, is typically a terminal stage of multiple myeloma and is associated with short survival.

According to the American Cancer Society there were approximately 231,840 new cases of invasive breast cancer last year in the USA and 40,290 deaths from breast cancer during the same period. Women represent 99% of all breast cancer patients. Breast cancer is treated by various combinations of surgery, radiation therapy, chemotherapy, and hormone therapy. TNBC is a type of breast cancer characterized by breast cancer cells that do not express estrogen receptors, progesterone receptors, or large amounts of HER2/neu protein. Approximately 10% - 20% percent of invasive breast cancers are diagnosed as triple-negative breast cancers. TNBC is more likely to affect younger people, African Americans or Hispanics, and those with a BRCA1 gene mutation. TNBC is insensitive to many of the most effective therapies available for the treatment of breast cancer including the HER2-directed therapy Herceptin® (trastuzumab), and endocrine therapies such as tamoxifen or the aromatase inhibitors. The relapse and survival rates of TNBC patients are shorter than for patients with other types of breast cancer. There is no current or pending drug therapy available for the treatment of TNBC.

Show more
Type
Public
HQ
Tampa, US
Founded
1965
Website
oxis.com
Oxis International was founded in 1965 and is headquartered in Tampa, US
Report incorrect company information

Oxis International Office Locations

Oxis International has an office in Tampa
Tampa, US (HQ)
600 100 Ashley Dr S
Show all (1)
Report incorrect company information

Oxis International Financials and Metrics

Oxis International Financials

USD

Net income (Q1, 2018)

(10.1 m)

EBIT (Q1, 2018)

(7.2 m)

Market capitalization (29-Jun-2017)

1.3 k

Closing share price (29-Jun-2017)

0.1

Cash (31-Mar-2018)

2.9 m

EV

(2.8 m)
Oxis International's current market capitalization is €1.3 k.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

342 k368 k61 k27 k

Revenue growth, %

8%(83%)(56%)(100%)

Sales and marketing expense

400 k

General and administrative expense

3.4 m935 k2.4 m8 m8.4 m
Quarterly
USDQ1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

88 k56 k183 k25 k3 k7 k20 k

General and administrative expense

366 k118 k200 k101 k112 k547 k1.6 m1.5 m2.6 m3.7 m5.5 m7.8 m1.4 m1 m126.3 m3.7 m

R&D expense

250 k225 k225 k475 k725 k144 k241 k526 k3.5 m

Operating expense total

366 k118 k201 k101 k112 k547 k1.8 m1.5 m2.8 m3.9 m6 m8.6 m1.5 m1.3 m126.9 m7.2 m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

123 k43 k855 k47 k19 k

Accounts Receivable

40 k4.5 k

Inventories

59 k42 k357.1 k251.8 k415.8 k

Current Assets

202 k125 k882 k49 k21 k
Quarterly
USDQ1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

11 k4 k1 k664 k1.4 m125 k42 k30 k355 k154 k235 k39 k2.7 m2.9 m

Accounts Receivable

30 k5 k

Inventories

94 k120 k40 k42 k26 k26 k

Current Assets

94 k131 k40 k77 k32 k690 k1.4 m127 k44 k32 k357 k156 k235 k39 k2.7 m2.9 m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(5.2 m)(501 k)(23.5 m)(32.7 m)21 m

Depreciation and Amortization

2 k1 k

Inventories

(47 k)17 k42 k(20 m)

Accounts Payable

480 k(276 k)880 k2.8 m
Quarterly
USDQ1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(147 k)(262 k)(4.9 m)(20.5 m)26.9 m(1.7 m)14.7 m16.2 m12.6 m(2.3 m)(10.1 m)

Depreciation and Amortization

1 k1 k1 k1 k1 k1 k1 k

Accounts Payable

161 k284 k445 k84 k179 k331 k(6 k)270 k1 m976 k1.5 m2.4 m523 k1.3 m(534 k)

Cash From Operating Activities

(138 k)(118 k)(73 k)(90 k)(133 k)(711 k)(1.8 m)(3.1 m)(3.7 m)(167 k)(1.2 m)(1.8 m)(650 k)(1 m)(4.2 m)
USDY, 2018

EV/EBIT

0.4 x

EV/CFO

0.7 x

Financial Leverage

1 x
Show all financial metrics

Oxis International Operating Metrics

FY, 2016

Patents Issued

2

Patents Pending

2
Show all operating metrics
Report incorrect company information

Oxis International Online and Social Media Presence

Embed Graph
Report incorrect company information